ACI

Albertsons Companies, Inc. - Q1 2024 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the 16-week period ended June 15, 2024 (First Quarter of Fiscal 2024). Albertsons Companies, Inc. is a major U.S. food retailer operating 2,269 stores across 34 states and the District of Columbia under banners including Albertsons, Safeway, and Vons. The company is currently subject to a pending Merger Agreement with The Kroger Co., which faces significant regulatory challenges and litigation.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 0.9% year-over-year, driven by a 1.4% increase in identical sales (excluding fuel) and a 23% increase in digital sales. Pharmacy sales grew significantly, while fuel sales declined.
• Profitability Decline: Net income decreased 42% to $240.7 million. This decline is largely attributable to the absence of a $49.7 million tax benefit in the prior year (related to the expiration of a foreign statute) and higher operating expenses.
• Expense Pressure: Selling and administrative expenses rose to 25.9% of sales (from 25.0%), driven by higher employee costs, digital development, and $92.3 million in merger-related costs.
• Debt Reduction: The company repaid $200.0 million on its ABL Facility, resulting in zero outstanding borrowings under that facility as of June 15, 2024.
• Impairment: Loss on property dispositions and impairment losses decreased to $5.3 million from $27.6 million in the prior year.

Guidance, Outlook, and Risks

Merger Status: The proposed merger with Kroger remains pending but faces substantial legal and regulatory hurdles. The FTC has instituted an administrative proceeding and filed suit seeking a preliminary injunction. State attorneys general in Washington and Colorado have also filed suits. The company has committed to not closing the merger until five days after the Washington state court rules. The outside date for the merger has been extended to October 9, 2024.

Liquidity: Management estimates liquidity needs of approximately $5.1 billion for the next 12 months, covering working capital, merger costs, capex, and dividends. The company maintains $3,954.2 million in available liquidity under its ABL Facility (net of letters of credit) and expects operating cash flows to meet obligations.

Legal Contingencies: Significant litigation includes:

• False Claims Act (FCA): Two consolidated cases regarding pharmacy pricing were remanded to lower courts following an adverse Supreme Court ruling. Trials are scheduled for late 2024 or 2025.
• Opioid Litigation: The company is a defendant in approximately 85 suits. Three bellwether trials are in discovery, with trial dates scheduled for 2025.
• PBM Litigation: A lawsuit challenging prescription drug price reporting is scheduled for trial in late 2025.

Outlook: The filing does not provide specific numerical guidance for the full fiscal year 2024, citing uncertainties related to the merger and macroeconomic conditions.

Investor Verification Checklist

• Merger Timeline: Monitor the status of the FTC administrative proceeding and state court injunction hearings scheduled for August and September 2024.
• Merger-Related Costs: Verify the trajectory of merger-related expenses ($92.3M in Q1) and their impact on future operating margins.
• Legal Reserves: Assess the adequacy of recorded liabilities for the FCA and Opioid litigation, given the adverse Supreme Court ruling on FCA pricing standards.
• Dividend Sustainability: Confirm the company's ability to maintain the $0.12 quarterly dividend amidst high merger costs and potential divestitures.
• Divestiture Plan: Track the progress of the divestiture agreement with C&S Wholesale Grocers, which is a condition for regulatory approval of the merger.